ReviewMaterials today. Bio2025
Immunomodulatory biomaterials for osteoarthritis: Targeting inflammation and enhancing cartilage regeneration.
Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Immune dysregulation in osteoarthritis: Mechanisms, biomarkers, and therapeutic opportunities.Journal of translational autoimmunity · 2026Review
- Compartmentalized Dual-Drug Injectable Hydrogel for Anti-Inflammatory Activity and Osteoarthritic Cartilage Repair.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- The Osteoimmunologic Basis of Biologic and Bioengineered Therapies in Osteoarthritis.Biomedicines · 2026Review
- Articular Cartilage Tissue Engineering: Cells, Bioinstructive Scaffolds, Immunological Microenvironment, and Emerging Technologies.Bioengineering (Basel, Switzerland) · 2026Review
- Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- The Infrapatellar Fat Pad in Osteoarthritis: From Pathophysiology to a Novel Therapeutic Target.International journal of molecular sciences · 2026Review
- Programmed cell death in osteoarthritis.Apoptosis : an international journal on programmed cell death · 2026Review
- An Injectable and Photocrosslinkable Hydrogel Based on Recombinant Human Collagen Type XVII Promotes Osteochondral Regeneration by Activating the TGF β/SMAD Signaling Pathway.Biomaterials research · 2026Article
- From Therapeutic Dilemma to Precision Modulation: Harnessing Biomaterials to Target the Dual Face of TGF-β in Osteoarthritis.Journal of inflammation research · 2026Review
- Nanotherapeutic Strategies for Osteoarthritis: Targeting Aging, Metabolism and Inflammation.International journal of nanomedicine · 2026Review
- Biofunctionalization of Stem Cell Scaffold for Osteogenesis and Bone Regeneration.Biomolecules · 2025Review
- Next-Generation Biomaterials: Design Strategies, Clinical Translation, and the Rise of Intelligent Therapeutic Platforms.ACS omega · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a prevalent joint disorder characterized by progressive cartilage degradation, impaired mesenchymal stem cell (MSC) function, and chronic inflammation, ultimately leading to irreversible structural damage and functional impairment. Despite its high global burden, no regulatory agency has yet approved a disease-modifying therapy for OA, and effective interventions to halt or delay its progression remain a major challenge. Recent research highlights the pivotal role of the immune system in OA pathogenesis, with immunomodulatory biomaterials emerging as a promising strategy to simultaneously regulate inflammatory responses and promote tissue regeneration. These biomaterials, by leveraging their biocompatibility and immunoregulatory properties, offer a transformative alternative to conventional OA therapies, which predominantly focus on symptom management rather than targeting the underlying disease mechanisms. In this review, we comprehensively examine various immunomodulatory biomaterial strategies designed to mitigate OA progression. We first elucidate the immune landscape of OA, detailing the interplay between inflammation and disease pathophysiology. Next, we explore the latest advancements in immunomodulatory biomaterials, including nanoparticles (NPs), hydrogels, and scaffolds, highlighting their potential to reshape OA treatment. Finally, we discuss existing challenges and propose future directions for optimizing biomaterial-based immunotherapies to enhance OA management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.